Kura Oncology KURA Stock
Kura Oncology Price Chart
Kura Oncology KURA Financial and Trading Overview
| Kura Oncology stock price | 5.71 USD |
| Previous Close | 11.47 USD |
| Open | 11.34 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 2200 |
| Day's Range | 10.93 - 11.5 USD |
| 52 Week Range | 9.49 - 19.93 USD |
| Volume | 2.04M USD |
| Avg. Volume | 742.26K USD |
| Market Cap | 750.09M USD |
| Beta (5Y Monthly) | 0.863028 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.09 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.1 USD |
KURA Valuation Measures
| Enterprise Value | 392.63M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.981818 |
| PEG Ratio (5 yr expected) | -0.26 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.8981642 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.748 |
Trading Information
Kura Oncology Stock Price History
| Beta (5Y Monthly) | 0.863028 |
| 52-Week Change | -22.87% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.93 USD |
| 52 Week Low | 9.49 USD |
| 50-Day Moving Average | 12.04 USD |
| 200-Day Moving Average | 13.17 USD |
KURA Share Statistics
| Avg. Volume (3 month) | 742.26K USD |
| Avg. Daily Volume (10-Days) | 1.3M USD |
| Shares Outstanding | 68.44M |
| Float | 47.88M |
| Short Ratio | 9.43 |
| % Held by Insiders | 1.94% |
| % Held by Institutions | 106.43% |
| Shares Short | 6.14M |
| Short % of Float | 9.10% |
| Short % of Shares Outstanding | 8.97% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.42% |
| Return on Equity (ttm) | -31.54% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -142860992 USD |
| Net Income Avi to Common (ttm) | -137456000 USD |
| Diluted EPS (ttm) | -1.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 405.9M USD |
| Total Cash Per Share (mrq) | 5.93 USD |
| Total Debt (mrq) | 13.54M USD |
| Total Debt/Equity (mrq) | 3.43 USD |
| Current Ratio (mrq) | 21.653 |
| Book Value Per Share (mrq) | 5.774 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -113753000 USD |
| Levered Free Cash Flow (ttm) | -65609248 USD |
Profile of Kura Oncology
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 12730 High Bluff Drive |
| ZIP | 92130 |
| Phone | 858 500 8800 |
| Website | https://kuraoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 131 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Q&A For Kura Oncology Stock
What is a current KURA stock price?
Kura Oncology KURA stock price today per share is 5.71 USD.
How to purchase Kura Oncology stock?
You can buy KURA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kura Oncology?
The stock symbol or ticker of Kura Oncology is KURA.
Which industry does the Kura Oncology company belong to?
The Kura Oncology industry is Biotechnology.
How many shares does Kura Oncology have in circulation?
The max supply of Kura Oncology shares is 86.57M.
What is Kura Oncology Price to Earnings Ratio (PE Ratio)?
Kura Oncology PE Ratio is now.
What was Kura Oncology earnings per share over the trailing 12 months (TTM)?
Kura Oncology EPS is -2.09 USD over the trailing 12 months.
Which sector does the Kura Oncology company belong to?
The Kura Oncology sector is Healthcare.
Kura Oncology KURA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19207.14 USD — |
+0.56
|
6.87B USD — | 19091.54 USD — | 19389.39 USD — | — - | 6.87B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 9397.76 USD — |
+0.53
|
— — | 9342.48 USD — | 9489.59 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4156.73 USD — |
+1.73
|
— — | 4085.23 USD — | 4162.64 USD — | — - | — — |
| Nasdaq Health Care IXHC | 953.67 USD — |
+1.31
|
— — | 942.74 USD — | 954.52 USD — | — - | — — |
- {{ link.label }} {{link}}